PDCD1 and melanoma: Monoclonal antibodies targeting the immune regulatory checkpoint receptors of anti-programmed cell death 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) have significantly improved the prognosis of patients with advanced melanoma [1,2,3,4].